14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)
Key Takeaways
- Vaginal infections are differentiated by physical characteristics, microscopic analysis, and pH: Bacterial Vaginosis (Amsel criteria: homogeneous thin grey discharge, pH >4.5, positive whiff test, >20% clue cells, absence of WBCs; treated with metronidazole 500 mg PO BID x 7 days); Vulvovaginal Candidiasis (thick white curd-like discharge, pH <4.5, hyphae/pseudohyphae; treated with fluconazole 150 mg PO); Trichomoniasis (frothy green discharge, strawberry cervix, pH >4.5, motile trichomonads and prominent PMNs on wet mount/NAAT; treated with metronidazole 500 mg PO BID x 7 days with mandatory partner treatment).
- Pelvic Inflammatory Disease (PID) is diagnosed clinically in sexually active women with lower abdominal/pelvic pain and at least ONE bimanual minimum criterion: cervical motion tenderness ('chandelier sign'), uterine tenderness, or adnexal tenderness; outpatient therapy requires Ceftriaxone 500 mg IM single dose PLUS Doxycycline 100 mg PO BID x 14 days PLUS Metronidazole 500 mg PO BID x 14 days, with mandatory 48-72 hour re-evaluation.
- Abnormal Uterine Bleeding (AUB) is categorized by the FIGO PALM-COEIN classification (Structural: Polyp, Adenomyosis, Leiomyoma, Malignancy; Non-structural: Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not classified); postmenopausal bleeding is endometrial adenocarcinoma until proven otherwise and requires urgent transvaginal ultrasound (TVUS) and/or endometrial biopsy.
- On transvaginal ultrasound for postmenopausal uterine bleeding, an endometrial stripe thickness (EMT) ≤4 mm carries a >99% negative predictive value for endometrial cancer; an EMT >4 mm or persistent bleeding requires gold-standard office Pipelle Endometrial Biopsy (EMB).
- USPSTF/ASCCP cervical cancer screening guidelines mandate cytology alone every 3 years for ages 21–29; for ages 30–65, options include high-risk HPV (hrHPV) alone every 5 years, hrHPV + cytology co-testing every 5 years, or cytology alone every 3 years; screening terminates at age 65 after adequate prior negative screening and no history of CIN 2+ in the preceding 25 years.
Last updated: August 2026
Gynecologic Infections, Abnormal Uterine Bleeding & Cervical Cancer Screening
Gynecologic complaints represent a major portion of primary care visits across the adult-gerontology spectrum. The AGPCNP must achieve mastery in distinguishing benign vaginal dysbiosis from invasive sexually transmitted infections, executing acute outpatient management for pelvic inflammatory disease, applying the FIGO PALM-COEIN classification to abnormal uterine bleeding, and navigating the 2019/2020 ASCCP risk-based guidelines for cervical cancer prevention.
1. Vaginal Ecology & Vaginitis Differential Diagnosis
The normal healthy vaginal ecosystem is dominated by hydrogen peroxide- and lactic acid-producing Lactobacillus species (L. crispatus, L. jensenii), which maintain an acidic vaginal $\text{pH}$ of $3.8\text{ to }4.5$. When this microenvironment is disrupted, pathological overgrowth or infectious vaginitis occurs.
+---------------------------------------------------------------------------------------------------+
| DIAGNOSTIC TRIAD OF INFECTIOUS VAGINITIS |
| |
| FEATURE BACTERIAL VAGINOSIS (BV) CANDIDIASIS (VVC) TRICHOMONIASIS |
| --------------------------------------------------------------------------------------------- |
| Etiology Polymicrobial dysbiosis Candida albicans (85-90%) Trichomonas vaginalis |
| (Gardnerella, Atopobium, Candida glabrata (10-15%) (Flagellated protozoan|
| Prevotella, Mobiluncus) - Sexually Transmitted|
| |
| Discharge Thin, homogeneous, off- Thick, white, clumpy, Copious, frothy, |
| white/gray, adherent "cottage cheese"-like yellow-green, malodor |
| |
| Symptoms Fishy malodor; mild Intense vulvar pruritus, Severe vulvar itching,|
| discharge; NO dyspareunia burning, dysuria, redness dyspareunia, dysuria |
| |
| Vaginal pH ELEVATED: >4.5 NORMAL: 3.8 - 4.5 ELEVATED: >4.5 (5-7) |
| |
| 10% KOH Whiff Test POSITIVE (Strong amine NEGATIVE OFTEN POSITIVE |
| fishy odor) (Mild amine odor) |
| |
| Microscopy CLUE CELLS (>20% squamous Pseudohyphae & budding MOTILE TRICHOMONADS |
| (Wet Mount) cells coated by coccobacilli; yeast spores on KOH; with flagella; |
| NO white blood cells/PMNs) Rare WBCs NUMEROUS PMNs / WBCs |
| |
| Physical Signs No mucosal inflammation Vulvar erythema, edema, "Strawberry Cervix" |
| fissures, excoriations (colpitis macularis) |
+---------------------------------------------------------------------------------------------------+
A. Bacterial Vaginosis (BV)
- Diagnostic Framework (Amsel Criteria): Diagnosis requires $\ge 3\text{ of the following 4 criteria}$:
- Homogeneous, thin, off-white/gray discharge that smoothly coats the vaginal walls.
- Vaginal $\text{pH} > 4.5$.
- Positive Whiff-Amine test (release of volatile putrescine/cadaverine fishy odor upon adding 1 drop of 10% KOH to discharge).
- Presence of Clue Cells on saline wet mount (vaginal epithelial cells whose borders are completely obscured/stippled by adherent coccobacilli, accounting for $>20%$ of all epithelial cells).
- Gold Standard: Nugent scoring of Gram stain (evaluates morphotypes: loss of Gram-positive Lactobacillus rods and predominance of Gram-negative/variable rods).
- CDC Recommended Treatment:
- Metronidazole 500 mg orally twice daily for 7 days (First-Line Gold Standard); OR
- Metronidazole 0.75% gel 5 g intravaginally once daily at bedtime for 5 days; OR
- Clindamycin 2% cream 5 g intravaginally at bedtime for 7 days.
- Clinical Pearl: Alcohol abstinence during oral metronidazole and for $\ge 24\text{ hours}$ after completion is essential to prevent severe disulfiram-like reactions (nausea, vomiting, flushing, tachycardia). Routine treatment of male sexual partners is not recommended.
B. Vulvovaginal Candidiasis (VVC)
- Diagnostic Confirmation: Saline or 10% KOH wet mount demonstrates fungal elements (pseudohyphae and budding blastospores). Vaginal $\text{pH}$ remains acidic and normal ($<4.5$).
- Classification & Treatment:
- Uncomplicated VVC (Sporadic, mild-to-moderate, C. albicans, immunocompetent):
- Fluconazole (Diflucan) 150 mg single oral dose; OR
- Intravaginal azoles (e.g., Clotrimazole 1% cream or Miconazole 200 mg suppository daily x 3 days).
- Complicated / Recurrent VVC ($\ge 4\text{ episodes/year}$, severe erythema/fissuring, uncontrolled diabetes, immunosuppression):
- Fluconazole 150 mg orally every 72 hours for 3 doses (Days 1, 4, and 7), followed by weekly maintenance Fluconazole 150 mg orally for 6 months.
- Non-albicans Candida (e.g., Candida glabrata - azole resistant):
- Boric acid gelatin capsules 600 mg intravaginally daily at bedtime for 14 days (Toxic if swallowed orally!).
- Uncomplicated VVC (Sporadic, mild-to-moderate, C. albicans, immunocompetent):
C. Trichomoniasis
- Etiology & Transmission: Trichomonas vaginalis, a flagellated, anaerobic, parasitic protozoan. It is a sexually transmitted infection (STI) associated with enhanced HIV transmission and preterm labor.
- Diagnostics: Wet mount shows motile, flagellated oval organisms and abundant polymorphonuclear leukocytes (PMNs). However, wet mount sensitivity is only 50–60%; Nucleic Acid Amplification Testing (NAAT) is the diagnostic gold standard ($>95%$ sensitivity).
- Updated CDC Treatment Guidelines:
- Women: Metronidazole 500 mg orally twice daily for 7 days (Multi-dose oral therapy has significantly higher cure rates than single-dose 2 g in women).
- Men: Metronidazole 2 g orally in a single dose.
- Mandatory Partner Management: Sexual partner(s) MUST be treated concurrently, and sexual intercourse avoided until both partners complete therapy and symptoms resolve. Retest all patients with NAAT at 3 months post-treatment.
2. Pelvic Inflammatory Disease (PID) & Tubo-Ovarian Abscess (TOA)
PID represents an acute, ascending polymicrobial infection of the upper female genital tract (endometrium, fallopian tubes, ovaries, and pelvic peritoneum).
+---------------------------------------------------------------------------------------------------+
| CDC CLINICAL DIAGNOSTIC CRITERIA FOR PID |
| |
| [MINIMUM CLINICAL CRITERIA (Presumptive Diagnosis)] |
| In a sexually active female at risk for STIs presenting with lower abdominal or pelvic pain, |
| initiate empiric treatment if AT LEAST ONE of the following is present on bimanual exam: |
| 1. CERVICAL MOTION TENDERNESS ("Chandelier Sign") |
| 2. UTERINE TENDERNESS |
| 3. ADNEXAL TENDERNESS (Unilateral or Bilateral) |
| (In the absence of any other identified etiology). |
| | |
| v |
| [ADDITIONAL SUPPORTING CRITERIA (Enhance Diagnostic Specificity)] |
| - Oral temperature >38.3°C (>101.0°F) |
| - Abnormal cervical or vaginal mucopurulent discharge or cervical friability |
| - Abundant white blood cells (WBCs) on saline wet mount of vaginal fluid |
| - Elevated Erythrocyte Sedimentation Rate (ESR) or C-Reactive Protein (CRP) |
| - Laboratory documentation of cervical infection with N. gonorrhoeae or C. trachomatis |
+---------------------------------------------------------------------------------------------------+
+---------------------------------------------------------------------------------------------------+
| CDC EMPIRIC TREATMENT PROTOCOLS FOR PID |
| |
| OUTPATIENT ORAL / INTRAMUSCULAR REGIMEN: |
| 1. CEFTRIAXONE: 500 mg IM in a single dose (1,000 mg if patient weight ≥150 kg) |
| PLUS |
| 2. DOXYCYCLINE: 100 mg orally twice daily for 14 FULL DAYS |
| PLUS |
| 3. METRONIDAZOLE: 500 mg orally twice daily for 14 FULL DAYS |
| (Metronidazole added to ensure anaerobic coverage and treat concomitant BV / Trichomonas) |
| |
| MANDATORY OUTPATIENT RE-EVALUATION: |
| - Patient MUST be clinically re-evaluated within 48 to 72 hours. |
| - If no substantial clinical improvement (reduction in pain, fever, tenderness), the patient |
| MUST BE HOSPITALIZED for inpatient parenteral therapy and pelvic ultrasound imaging. |
| |
| CRITERIA MANDATING INPATIENT HOSPITALIZATION FOR PID: |
| - Surgical emergencies cannot be excluded (e.g., Acute Appendicitis) |
| - Suspected Tubo-Ovarian Abscess (TOA) on ultrasound |
| - Pregnancy |
| - Severe illness, high fever (>38.5°C), nausea, intractable vomiting, or peritonitis |
| - Inability to tolerate or adhere to outpatient oral antimicrobial regimen |
| - Lack of clinical response to outpatient therapy within 72 hours |
+---------------------------------------------------------------------------------------------------+
Long-Term PID Sequelae
- Tubal Factor Infertility: Occurs in 8% after 1 episode of PID, 20% after 2 episodes, and $>40%$ after 3+ episodes due to post-inflammatory tubal scarring and occlusion.
- Ectopic Pregnancy: Relative risk increases 7- to 10-fold following salpingitis.
- Chronic Pelvic Pain: Develops in ~30% due to dense pelvic adhesions.
- Fitz-Hugh-Curtis Syndrome (Perihepatitis): Inflammation of the hepatic capsule with "violin-string" adhesions between the liver surface and anterior abdominal wall, presenting as sharp right upper quadrant (RUQ) pleuritic pain mimicking acute cholecystitis.
3. Abnormal Uterine Bleeding (AUB) & FIGO Classification
Abnormal Uterine Bleeding in non-pregnant reproductive-age women is standardized under the FIGO PALM-COEIN classification system:
+---------------------------------------------------------------------------------------------------+
| FIGO PALM-COEIN CLASSIFICATION FOR AUB |
| |
| [STRUCTURAL CAUSES (PALM) - Measured by Imaging / Histopathology] |
| P - POLYP -> Endometrial or endocervical polyps; intermenstrual spotting |
| A - ADENOMYOSIS -> Ectopic endometrial glands in myometrium; enlarged, boggy, uniformly |
| tender uterus with menorrhagia and severe dysmenorrhea |
| L - LEIOMYOMA -> Uterine fibroids (Submucosal causing profound menorrhagia/anemia; |
| Subserosal/Intramural causing bulk symptoms); firm, irregular uterus |
| M - MALIGNANCY -> Endometrial hyperplasia or adenocarcinoma; cervical carcinoma |
| |
| [NON-STRUCTURAL CAUSES (COEIN) - Laboratory / Endocrine / Clinical Etiologies] |
| C - COAGULOPATHY -> von Willebrand disease (heavy menses since menarche), thrombocytopenia |
| O - OVULATORY -> Anovulatory bleeding: PCOS, thyroid disease, hyperprolactinemia, obesity |
| E - ENDOMETRIAL -> Primary disorder of local endometrial hemostatic mechanisms (PGF2a/PGE2) |
| I - IATROGENIC -> IUDs, subdermal implants, anticoagulants, psychotropic drugs |
| N - NOT CLASSIFIED -> Arteriovenous malformations, rare vascular lesions |
+---------------------------------------------------------------------------------------------------+
Workup and Management of Postmenopausal Bleeding (PMB)
Postmenopausal vaginal bleeding is Endometrial Cancer until proven otherwise! Any vaginal bleeding occurring $\ge 12\text{ months}$ after the final menstrual period demands immediate objective diagnostic investigation.
+---------------------------------------------------------------------------------------------------+
| POSTMENOPAUSAL UTERINE BLEEDING WORKUP ALGORITHM |
| |
| [POSTMENOPAUSAL PATIENT PRESENTS WITH EPISODIC OR CONTINUOUS UTERINE BLEEDING] |
| | |
| v |
| [TRANSVAGINAL ULTRASOUND (TVUS) - FIRST-LINE NON-INVASIVE ASSESSMENT] |
| - Measure Endometrial Thickness (EMT) double-layer stripe in the sagittal plane. |
| | |
| +------------------------+------------------------+ |
| | | |
| v v |
| [EMT ≤ 4.0 mm] [EMT > 4.0 mm OR FLUID/HETEROGENEITY] |
| - Negative predictive value for - High risk for hyperplasia / cancer. |
| endometrial cancer >99%. - IMMEDIATE ACTION: Perform Gold-Standard |
| - Management: Clinical observation. OFFICE PIPELLE ENDOMETRIAL BIOPSY (EMB). |
| - Caveat: If bleeding recurs or - If EMB is non-diagnostic or bleeding |
| persists -> MUST PROCEED TO EMB! persists -> Proceed to Hysteroscopy + D&C. |
+---------------------------------------------------------------------------------------------------+
4. Cervical Cancer Screening & 2019/2020 ASCCP Risk Guidelines
A. USPSTF Cervical Cancer Screening Recommendations (Average-Risk Women)
+---------------------------------------------------------------------------------------------------+
| USPSTF CERVICAL CANCER SCREENING SCHEDULE |
| |
| AGE GROUP RECOMMENDED SCREENING STRATEGY USPSTF GRADE |
| --------------------------------------------------------------------------------------------- |
| <21 years DO NOT SCREEN (regardless of sexual history) Grade D (Discouraged) |
| |
| 21 - 29 years Cervical Cytology (Pap Smear) alone EVERY 3 YEARS Grade A (Recommended) |
| (Do NOT screen with hrHPV co-testing or primary HPV) |
| |
| 30 - 65 years THREE ACCEPTABLE EVIDENCE-BASED STRATEGIES: Grade A (Recommended) |
| 1. High-Risk HPV (hrHPV) alone EVERY 5 YEARS, OR |
| 2. hrHPV + Cytology Co-Testing EVERY 5 YEARS, OR |
| 3. Cervical Cytology alone EVERY 3 YEARS |
| |
| >65 years DISCONTINUE SCREENING IF adequate prior negative Grade D (Discouraged) |
| screening AND no history of CIN 2, CIN 3, or AIS |
| in the past 25 years. |
| (Adequate prior negative: 3 consecutive negative Pap |
| smears OR 2 consecutive negative co-tests in last 10 |
| years, with the most recent test within 5 years). |
| |
| Post-Total DISCONTINUE SCREENING IF cervix removed for benign Grade D (Discouraged) |
| Hysterectomy indications and no history of CIN 2+ or cancer. |
+---------------------------------------------------------------------------------------------------+
B. ASCCP 2019/2020 Risk-Based Consensus Guidelines
The American Society for Colposcopy and Cervical Pathology (ASCCP) shifted management from rigid test-result algorithms to individualized risk-based thresholds, estimating immediate and 5-year risk of Cervical Intraepithelial Neoplasia Grade 3 or worse (CIN 3+).
+---------------------------------------------------------------------------------------------------+
| ASCCP RISK-BASED CLINICAL ACTION THRESHOLDS |
| |
| ESTIMATED IMMEDIATE RISK OF CIN 3+ MANDATED CLINICAL ACTION |
| --------------------------------------------------------------------------------------------- |
| Immediate Risk ≥ 60% Expedited Treatment (LEEP) or Colposcopy |
| Immediate Risk 25% to 59% Expedited Treatment (LEEP) or Colposcopy |
| Immediate Risk 4.0% to 24% COLPOSCOPY MANDATED |
| Immediate Risk < 4.0% SURVEILLANCE (Return at 1, 3, or 5 years) |
| - 5-year risk ≥ 0.55% -> 1-year follow-up (repeat hrHPV / co-testing) |
| - 5-year risk 0.15% to 0.54% -> 3-year follow-up |
| - 5-year risk < 0.15% -> 5-year routine return |
+---------------------------------------------------------------------------------------------------+
+---------------------------------------------------------------------------------------------------+
| PRACTICAL CLINICAL ASCCP MANAGEMENT PATHWAYS |
| |
| 1. HPV 16 or HPV 18 POSITIVE (Any Cytology): |
| - HPV 16/18 are responsible for 70% of invasive cervical cancers. |
| - ACTION: Immediate COLPOSCOPY regardless of whether cytology is normal or abnormal. |
| |
| 2. HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL): |
| - Immediate CIN 3+ risk exceeds 25%. |
| - ACTION: COLPOSCOPY or direct EXPEDITED TREATMENT (LEEP excisional procedure). |
| |
| 3. ATYPICAL SQUAMOUS CELLS - CANNOT EXCLUDE HIGH-GRADE (ASC-H): |
| - High risk of underlying high-grade dysplasia. |
| - ACTION: Immediate COLPOSCOPY. |
| |
| 4. ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE (ASC-US): |
| - Reflex hrHPV Negative -> Repeat Cytology / Co-testing in 3 YEARS. |
| - Reflex hrHPV Positive -> Immediate COLPOSCOPY. |
| |
| 5. LOW-GRADE SQUAMOUS INTRAEPITHELIAL LESION (LSIL): |
| - LSIL with hrHPV Positive -> Immediate COLPOSCOPY. |
| - LSIL with hrHPV Negative -> Repeat Co-testing in 1 YEAR. |
| |
| 6. hrHPV POSITIVE WITH NORMAL (NILM) CYTOLOGY (Age ≥30): |
| - Option A: Reflex Genotyping for HPV 16/18. If 16/18 positive -> COLPOSCOPY; if 16/18 negative|
| -> Repeat Co-testing in 1 YEAR. |
| - Option B: Repeat Co-testing in 1 YEAR. If persistent hrHPV+ or abnormal cytology at 1 year |
| -> COLPOSCOPY. |
+---------------------------------------------------------------------------------------------------+
5. Gynecologic Oncology Red Flags: Ovarian & Endometrial Cancer
| Malignancy | Cardinal Epidemiology & Risk Factors | Hallmark Symptoms & Physical Exam | Diagnostic Strategy & Screening Rules |
|---|---|---|---|
| Endometrial Cancer | Most common GYN cancer; unopposed estrogen, obesity ($BMI \ge 30$), nulliparity, PCOS, Tamoxifen, Lynch syndrome. | Postmenopausal bleeding (PMB); abnormal intermenstrual or heavy prolonged bleeding. | Transvaginal ultrasound ($EMT >4\text{ mm}$ triggers biopsy); Pipelle Endometrial Biopsy is definitive. NO routine screening. |
| Ovarian Cancer | Highest mortality GYN cancer; age $>60$, BRCA1/2 mutations, Lynch syndrome, nulliparity, family history. | Non-specific: Persistent abdominal bloating, pelvic fullness, early satiety, urinary urgency $>2-3$ weeks; fixed solid adnexal mass. | Transvaginal ultrasound + Serum CA-125. USPSTF Grade D: DO NOT screen asymptomatic average-risk women with CA-125/TVUS. |
| Cervical Cancer | Persistent high-risk HPV (16, 18, 31, 33, 45), immunosuppression/HIV, tobacco smoking, high parity. | Postcoital vaginal bleeding, watery malodorous bloody discharge, visible friable exophytic cervical mass. | ASCCP guideline-directed Cytology/hrHPV screening; Colposcopy with targeted cervical biopsies. |
6. Board-Yield Summary & Clinical Pearls
+---------------------------------------------------------------------------------------------------+
| ANCC AGPCNP CLINICAL EXAM PEARLS |
| |
| - Bacterial Vaginosis shows clue cells and elevated pH (>4.5) with NO white blood cells (WBCs); |
| Trichomoniasis shows motile flagellated organisms, elevated pH (>4.5), and ABUNDANT WBCs. |
| |
| - Always treat Trichomoniasis with METRONIDAZOLE 500 mg PO BID for 7 days in women (not single |
| dose), and ALWAYS treat the sexual partner concurrently! |
| |
| - Empiric PID outpatient regimen: CEFTRIAXONE 500 mg IM x 1 + DOXYCYCLINE 100 mg PO BID x 14 d |
| + METRONIDAZOLE 500 mg PO BID x 14 d. Mandate clinical re-evaluation in 48-72 hours. |
| |
| - Postmenopausal uterine bleeding is ENDOMETRIAL CANCER until proven otherwise. Endometrial |
| stripe thickness ≤4 mm on TVUS rules out cancer with >99% NPV; >4 mm requires Pipelle Biopsy. |
| |
| - Cervical screening NEVER begins before age 21 regardless of sexual debut (Grade D). |
| |
| - Any positive HPV 16 or HPV 18 test mandates immediate COLPOSCOPY regardless of Pap cytology! |
| |
| - Ovarian cancer screening with CA-125 or pelvic ultrasound in asymptomatic average-risk women |
| is strictly HARMFUL and contraindicated (USPSTF Grade D). |
+---------------------------------------------------------------------------------------------------+
Test Your Knowledge
A 23-year-old female presents to the urgent care clinic complaining of lower abdominal pain, dyspareunia, and an abnormal vaginal discharge for 4 days. She has a new male sexual partner over the past 2 months. Physical examination reveals an oral temperature of 38.4°C (101.1°F), heart rate of 88 bpm, and blood pressure of 116/74 mmHg. Abdominal exam reveals moderate bilateral lower quadrant tenderness without guarding or rebound. Speculum exam reveals purulent endocervical discharge and cervical friability. Bimanual exam reveals exquisite cervical motion tenderness and bilateral adnexal tenderness without a palpable adnexal mass. Wet mount confirms abundant polymorphonuclear leukocytes. What is the most appropriate next clinical step and outpatient pharmacologic regimen?
A
B
C
D
Test Your Knowledge
A 32-year-old female presents for a routine well-woman preventive visit. She has no chronic medical conditions and has had normal cervical cytology in the past. Cervical cancer co-testing (cytology plus high-risk HPV) is performed. The laboratory results return revealing negative for intraepithelial lesion or malignancy (NILM / normal Pap cytology), but positive for high-risk HPV genotype 16. According to the 2019/2020 ASCCP Risk-Based Management Consensus Guidelines, what is the most appropriate clinical action?
A
B
C
D
Test Your Knowledge
A 58-year-old postmenopausal female presents to the primary care clinic reporting two episodes of light, painless vaginal bleeding over the past 3 weeks. Her natural menopause occurred 6 years ago, and she has had no previous postmenopausal bleeding. She takes no medications and has never used hormone replacement therapy. Physical examination is unremarkable, with a normal atrophic vulva and cervix. What is the AGPCNP's immediate diagnostic priority?
A
B
C
D